IP Library Granted Patent US 8,835,172
Granted Patent B2
US 8,835,172 · App. 13/621,880 · Granted Sep 16, 2014

Modular functional peptides for delivery of nanoparticles

Inventors: James B. Delehanty (Washington, DC); Igor L. Medintz (Springfield, VA); Hedi M. Mattoussi (Tallahassee, FL); Jeffrey R. Deschamps (Laurel, MD); Glyn Dawson (Chicago, IL); Philip E. Dawson (San Diego, CA); Juan Bautista Blanco-Canosa (A Coruna, ES); Kelly Boeneman (Arlington, VA)
Assignee: The United States of America, as represented by the Secretary of the Navy
C12N5/0006A61K49/0067A61K49/0056A61K49/0054G01N33/588C07K17/14B82Y5/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,835,172
App. No.
13/621,880
Granted
Sep 16, 2014
Kind
B2
Abstract

A peptide directs nanoparticles (such as quantum dots) to the plasma membrane of mammalian cells. A method of delivery of a nanoparticle to a plasma membrane of a cell includes providing to the cell a nanoparticle attached to a peptide configured to direct the nanoparticle the plasma membrane, and allowing the cell to take up the nanoparticle. The nanoparticle can be a FRET donor to an organic dye.

Claims (16)

1. A method of labeling a plasma membrane of a cell, the method comprising:

providing to the cell an organic fluorescent dye adapted to partition to the plasma membrane;

providing to the cell a nanoparticle attached to a peptide comprising JB858, wherein the nanoparticle is a FRET donor to the organic fluorescent dye; and

photo-exciting the nanoparticle to obtain fluorescence from the organic fluorescent dye in plasma membrane of the cell.

2. The method of claim 1 , wherein the nanoparticle is a quantum dot.

3. A method of labeling a mammalian cell, the method comprising:

providing to the cell a first nanoparticle attached to a first peptide comprising JB858; and

providing to the cell a second nanoparticle attached to a second peptide comprising (a) a nanoparticle association domain, (b) a spacer domain, (c) an uptake domain, and (d) a vesicle escape domain comprising a non-hydrolyzable lipid moiety, wherein the spacer domain is between the nanoparticle association domain and the uptake and vesicle escape domains, and wherein the second peptide attached to the second nanoparticle is effective to induce uptake of the second nanoparticle by the cell and delivery of the second nanoparticle to the cytosol of the cell.

4. The method of claim 3 , wherein the first nanoparticle and/or the second nanoparticle are quantum dots.

5. The method of claim 3 , further comprising providing to the cell an organic fluorescent dye adapted to partition to the plasma membrane, wherein the first nanoparticle is a FRET donor to the organic fluorescent dye.

6. A method of delivery of a nanoparticle to a plasma membrane of a cell, the method comprising:

providing to the cell a nanoparticle attached to a peptide comprising JB858,

and allowing the cell to take up the nanoparticle.

7. The method of claim 6 , wherein the nanoparticle is a quantum dot.

8. The method of claim 6 , whereby said providing results in inhibiting endocytosis in the cell.

9. The method of claim 8 , wherein the nanoparticle is a quantum dot.

Assignments (1)
CONFIRMATORY LICENSE Recorded Sep 1, 2020
From: UNIVERSITY OF CHICAGO
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 053656/0630 →
Continuity (3)
Continuation In Part 12908601 · Oct 20, 2010
Provisional Application 61253921 · Oct 22, 2009
Related Publication 20130130296A1 · May 23, 2013